1,4-Diethyl-imidazole | 21486-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,4-Diethyl-imidazole
• 英文别名: 1,4-diethyl-1H-imidazole；1,4-Diethyl-1H-imidazole；1,4-diethylimidazole
• CAS: 21486-93-1
• 化学式: C₇H₁₂N₂
• 分子量: 124.186
• InChiKey: FNOZYFSGNFPIIH-UHFFFAOYSA-N

物化性质

• 沸点：
  74-75 °C(Press: 2 Torr)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• NITROGEN-CONTAINING HETEROARYL DERIVATIVES
  申请人：Bleicher Konrad

  公开号：US20110183979A1

  公开（公告）日：2011-07-28

  The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明涉及式(I)的新氮杂芳基衍生物，其中R1、R2、R3、R4、R5、A1、A2和Y的定义如描述和权利要求中所述，以及这些化合物的生理可接受的盐和酯。这些化合物可以抑制PDE10A，并可作为药物使用。
• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• [EN] RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
  申请人：PROVINCIAL HEALTH SERVICES AUTHORITY

  公开号：WO2020252598A1

  公开（公告）日：2020-12-24

  A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be –CO2H, –SO2H, –SO3H, –PO2H, or –PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

  一种化合物，包括以下结构式或其盐或溶剂化合物的前列腺特异性膜抗原（PSMA）靶向基团。R0为O或S。R1a、R1b和R1c中的每一个可以是-CO2H、-SO2H、-SO3H、-PO2H或-PO3H2，例如。R2可以是亚甲基或其衍生物、丙烯基或其衍生物，或乙烯的衍生物，可选择性地取代。R3是一个连接基。当PSMA靶向基团与放射标记基团连接时，该化合物可用作PSMA表达疾病/病况的成像剂或治疗剂。
• INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Saavedra Mario Oscar

  公开号：US20080064718A1

  公开（公告）日：2008-03-13

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号和HGF受体信号的传导。更具体地，本发明涉及用于抑制VEGF受体信号和HGF受体信号的化合物、组合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
• KINASE INHIBITORS AND USES THEREOF
  申请人：Raeppel Stephane

  公开号：US20080255155A1

  公开（公告）日：2008-10-16

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds, compositions and methods for the inhibition of kinase activity. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，本发明涉及抑制激酶活性的化合物、组合物和方法。本发明还提供用于治疗细胞增殖性疾病和病症的化合物、组合物和方法。